Novartis (NYSE: NVS ) is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios.
However, Novartis is facing significant threats from competitors Biogen Idec (NASDAQ: BIIB ) and Regeneron (NASDAQ: REGN ) which could crimp sales even as generic competition heats up for Novartis' multi-billion blockbuster drug Diovan.
In the following slideshow, you'll learn more about Novartis' most important drugs and the threats and opportunities the lie ahead for them.
Novartis will have a tough time keeping up with these top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.